| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/24/2002 | US6455283 Amino acid sequence of polypeptide; for recombinant cell culture production of this growth factor; anticarcinogenic agents; wound healing agents |
| 09/24/2002 | US6455278 Nucleic acid which encodes protein of defined amino acid sequence involved in pain perception; analgesics |
| 09/24/2002 | US6455076 Formulations and methods for reducing skin irritation |
| 09/24/2002 | US6455074 Methods of forming and using the device for the sustained release of an active agent. the improved method of the invention for forming a polymer-based sustained release device comprises forming a polymer/active agent solution by mixing a |
| 09/24/2002 | US6455070 For therapy of symptoms of colds and flu in humans |
| 09/24/2002 | US6455063 A ruminant direct fed microbial composition of matter comprising an acidosis inhibiting effective amount of propionibacterum p-63 is provided. a process for reducing acidosis in ruminants or scours in swine by administration of |
| 09/24/2002 | US6455061 Mixture containing n-acetylcysteine, lysine hydrochloride, 2-amino-2-deoxyglucose and magnesium compound |
| 09/24/2002 | US6455060 S(+) desmethylselegiline and its use to treat immune system dysfunction |
| 09/24/2002 | US6455040 Sometimes referred to as ?tnfr-5? or ?tr5,? and now referred to hereinafter as ?trail receptor without intracellular domain? or ?trid.? |
| 09/23/2002 | CA2341952A1 Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| 09/19/2002 | WO2002073213A2 Assay |
| 09/19/2002 | WO2002073208A2 Anti-epileptogenic agents |
| 09/19/2002 | WO2002072888A2 Polymorphisms in the human cmoat gene and uses thereof |
| 09/19/2002 | WO2002072830A2 Proteins associated with cell growth, differentiation, and death |
| 09/19/2002 | WO2002072822A2 Als2 gene and amyotrophic lateral sclerosis type 2 |
| 09/19/2002 | WO2002072794A2 Immunoglobulin superfamily proteins |
| 09/19/2002 | WO2002072790A2 Tsg101-gag interaction and use thereof |
| 09/19/2002 | WO2002072788A2 Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses |
| 09/19/2002 | WO2002072780A2 Igf antagonist peptides |
| 09/19/2002 | WO2002072776A2 Cell culture system for synthesis of infectious hepatitis c virus |
| 09/19/2002 | WO2002072631A2 Mhc molecule constructs and their usesfor diagnosis and therapy |
| 09/19/2002 | WO2002072630A2 Nucleic acid-associated proteins |
| 09/19/2002 | WO2002072618A1 Novel peptide ligands of leukocyte integrins |
| 09/19/2002 | WO2002072569A1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same |
| 09/19/2002 | WO2002072544A2 Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 09/19/2002 | WO2002072543A2 Rxr activating molecules |
| 09/19/2002 | WO2002072534A2 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof |
| 09/19/2002 | WO2002072527A2 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 09/19/2002 | WO2002072148A1 Compositions and methods for non-insulin glucose uptake |
| 09/19/2002 | WO2002072147A1 Medicinal compositions containing bile acid transporter inhibitor |
| 09/19/2002 | WO2002072146A2 Combination of nateglinide or repaglinide with at least one further antidiabetic compound |
| 09/19/2002 | WO2002072132A1 Combinations of heparin cofactor ii agonist and platelet iib/iiia antagonist, and uses thereof |
| 09/19/2002 | WO2002072127A2 Modulation of smooth muscle cell proliferation by vegf-x or antagonists thereof |
| 09/19/2002 | WO2002072108A1 Use of fluticasone propionate in the treatment of diseases ameliorated by enhancement of epithelial/matrix adhesion such as asthma, cystic fibrosis and influenza |
| 09/19/2002 | WO2002072106A2 Combined method for treating hormono-dependent disorders with exemestane |
| 09/19/2002 | WO2002072104A2 Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
| 09/19/2002 | WO2002072098A1 Method of treatment |
| 09/19/2002 | WO2002072096A1 Acridines as stimulators for fas-mediated apoptosis |
| 09/19/2002 | WO2002072094A2 Use of neuroactive substances and combinations thereof for the treatment of parkinsons disease |
| 09/19/2002 | WO2002072093A2 Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders |
| 09/19/2002 | WO2002072091A1 Anticancer drug-tolerance inhibitors |
| 09/19/2002 | WO2002072090A1 Benzimidazole compounds for modulating ige and inhibiting cellular proliferation |
| 09/19/2002 | WO2002072088A2 Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases |
| 09/19/2002 | WO2002072085A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 09/19/2002 | WO2002072080A2 Paracetamol solutions which are stable in storage and ready for infusion |
| 09/19/2002 | WO2002072078A2 Use of sugar phosphates, amino acids, amino acid analogs, e.g. carbomethoxypropionyl cyanide for reducing weight or diabetes complications |
| 09/19/2002 | WO2002072071A1 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor |
| 09/19/2002 | WO2002072070A1 Method to obtain microparticles containing a h+, k+-atp-ase inhibitor |
| 09/19/2002 | WO2002072066A1 Composition for rectal delivery of an oxazolidinone antibacterial drug |
| 09/19/2002 | WO2002072031A2 Substituted tetracycline compounds as synergistic antifungal agents |
| 09/19/2002 | WO2002072010A2 Taxane prodrugs |
| 09/19/2002 | WO2002072008A2 Method for treating cancer using a33 specific antibodies and chemotherapeutic agents |
| 09/19/2002 | WO2002072003A2 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 09/19/2002 | WO2002071874A2 Composition improving age-related physiological deficits and increasing longevity |
| 09/19/2002 | WO2002071827A2 Retinoid x receptor modulators |
| 09/19/2002 | WO2002062361A9 Antiviral composition containing propolis and essential oils |
| 09/19/2002 | WO2002055663A3 Srebp pathway modulation through targeting hisrs |
| 09/19/2002 | WO2002053138A3 Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
| 09/19/2002 | WO2002052934A3 Pesticidal and antiparasitic compositions |
| 09/19/2002 | WO2002050119A3 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| 09/19/2002 | WO2002049624A3 Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists |
| 09/19/2002 | WO2002036106A3 Novel medicament compositions based on anticholinergics and corticosteroids |
| 09/19/2002 | WO2002033079A3 Human g-protein coupled receptor and uses thereof |
| 09/19/2002 | WO2002032374A3 Methods for treating il-18 mediated disorders |
| 09/19/2002 | WO2002024695A3 Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines |
| 09/19/2002 | WO2002024194A9 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| 09/19/2002 | WO2002020841A3 5-hydroxytryptamine receptor gene polymorphisms and response to treatment |
| 09/19/2002 | WO2002018553A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/19/2002 | WO2002017949A9 Novel functions for dp214 |
| 09/19/2002 | WO2002010382A9 Trp8, trp9 and trp10, markers for cancer |
| 09/19/2002 | WO2002010192A3 Somatostatin analogues |
| 09/19/2002 | WO2002005792A9 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 09/19/2002 | WO2002002610A3 Secretion and trafficking molecules |
| 09/19/2002 | WO2001085956A3 Lipid metabolism enzymes |
| 09/19/2002 | WO2001064949A3 Diagnostics and therapeutics for glaucoma |
| 09/19/2002 | WO2001035899A9 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 09/19/2002 | WO2001019360A3 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| 09/19/2002 | US20020133835 Genetically engineering vertebrate germ cells; obtain gonads, incubate in transfection mixture and nucleotide sequences, transfect, recover transfected germ cells |
| 09/19/2002 | US20020133001 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| 09/19/2002 | US20020132979 Monoclonal antibody for use in the diagnosis, prevention and treatment of tumors |
| 09/19/2002 | US20020132978 VEGF-modulated genes and methods employing them |
| 09/19/2002 | US20020132855 Or salts, esters or ethers of acetaminophen to prevent and treat arteriosclerosis and atherosclerosis |
| 09/19/2002 | US20020132835 Treatment of Infant Respiratory Distress Syndrome or Adult Respiratory Distress Syndrome by administering a combination of a phospholipid lung surfactant with N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide |
| 09/19/2002 | US20020132832 Administering a compound which attenuates RhoA and/or Rho-kinase activity in an organ subject to sexual stimulation to treat male and female sexual dysfunction |
| 09/19/2002 | US20020132830 Use of beta 2 bronchodilator drugs |
| 09/19/2002 | US20020132827 Using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, "off-period." |
| 09/19/2002 | US20020132825 Analgesic combination of oxycodone and celecoxib |
| 09/19/2002 | US20020132814 AcrAB-like efflux pumps control resistance to drugs, even in highly resistant microbes; combination of an inhibitor of an AcrAB-like efflux pump and an antibiotic |
| 09/19/2002 | US20020132808 Useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic; also are useful as anticancer agents. |
| 09/19/2002 | US20020132806 Treatment of atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X |
| 09/19/2002 | US20020132795 Methods for treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compounds |
| 09/19/2002 | US20020132791 Beta-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases |
| 09/19/2002 | US20020132781 Optionally a glutathione pathway enhancing and detoxifying compound, particularly cystine |
| 09/19/2002 | US20020132778 Modulating angiogenesis |
| 09/19/2002 | US20020132764 Cyclosporin; mycophenolic acid or its salt as an immunosuppressor; and rapamycin or a derivative |
| 09/19/2002 | US20020132755 Histamine receptor antagonists |
| 09/19/2002 | US20020132754 Producing pharmaceuticals for improving perception, concentration, learning and/or memory. |
| 09/19/2002 | US20020132342 Generating immortalized dendritic cells; obtain cells, culture, maintain culture of dendritic cells, monitor gene expression from cell culture |
| 09/19/2002 | US20020132330 Polypeptide for use in the treatment, prevention and diagnosis of inflammation, cell proliferation and apoptosis |
| 09/19/2002 | US20020132324 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |